3 results match your criteria: "Ellen and Martin Prosserman Centre for Neuromuscular Disease[Affiliation]"

Objective: Motor neuron disease (MND) is a group of neurological diseases, the majority being amyotrophic lateral sclerosis (ALS), with varying clinical presentations across demographics. Clinical trial enrollment reflecting global disease burden improves understanding of diverse presentations and aids personalized therapy development. We assessed the sex, racial, and ethnic composition of MND/ALS clinical trial participants relative to global disease burdens.

View Article and Find Full Text PDF

Introduction: Current guidelines for defining good outcomes in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) are predominately defined by experts. At present, we do not have a patient-anchored definition of what constitutes a "good" outcome. Our study aimed to assess the symptom burden of people living with CIDP, as well as satisfaction with treatments and clinical outcomes.

View Article and Find Full Text PDF

Patient-acceptable symptom states in myasthenia gravis.

Neurology

September 2020

From the Ellen and Martin Prosserman Centre for Neuromuscular Disease (M.M., V.B., H.D.K., C.B.), Toronto General Hospital; and Division of Neurology (C.T., V.B., H.D.K., C.B.), University Health Network and University of Toronto, Ontario, Canada.

Objectives: To estimate patient-acceptable symptom state (PASS) cut points for myasthenia gravis (MG) health scales.

Methods: We conducted an electronic survey that included the Myasthenia Gravis Impairment Index (MGII), EuroQol 5-Dimension (EQ5D), and a simple PASS question. PASS-anchored thresholds were estimated for the MGII questionnaire through receiver operating characteristic curves.

View Article and Find Full Text PDF